United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
United Therapeutics (Nasdaq: UTHR) has announced it will release its third quarter 2024 financial results before market opening on Wednesday, October 30, 2024. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time. The webcast will be accessible through the company's investor relations website and will remain available for replay for one year.
United Therapeutics (Nasdaq: UTHR) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato mercoledì 30 ottobre 2024. L'azienda emetterà un comunicato stampa dettagliato alle 6:30 (ora orientale), seguito da un webcast pubblico alle 9:00 (ora orientale). Il webcast sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda e resterà disponibile per la riproduzione per un anno.
United Therapeutics (Nasdaq: UTHR) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el miércoles, 30 de octubre de 2024. La compañía emitirá un comunicado de prensa detallado aproximadamente a las 6:30 a.m. hora del Este, seguido de un webcast público a las 9:00 a.m. hora del Este. El webcast será accesible a través del sitio web de relaciones con inversores de la compañía y estará disponible para repetición durante un año.
유나이티드 테라퓨틱스 (Nasdaq: UTHR)가 2024년 3분기 재무 결과를 2024년 10월 30일 수요일 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 동부 표준시로 오전 6시 30분경에 상세한 보도 자료를 발행하며, 이어서 동부 표준시로 오전 9시에 공개 웹 세미나를 진행할 예정입니다. 이 웹 세미나는 회사의 투자자 관계 웹사이트를 통해 접근 가능하며, 1년 동안 재생할 수 있습니다.
United Therapeutics (Nasdaq: UTHR) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés le mercredi 30 octobre 2024. L'entreprise publiera un communiqué de presse détaillé vers 6h30, heure de l'Est, suivi d'un webinaire public à 9h00, heure de l'Est. Le webinaire sera accessible via le site Web des relations avec les investisseurs de l'entreprise et sera disponible en replay pendant un an.
United Therapeutics (Nasdaq: UTHR) hat bekannt gegeben, dass die Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am Mittwoch, den 30. Oktober 2024, veröffentlicht werden. Das Unternehmen wird um etwa 6:30 Uhr Eastern Time eine detaillierte Pressemitteilung herausgeben, gefolgt von einem öffentlichen Webcast um 9:00 Uhr Eastern Time. Der Webcast wird über die Investor-Relations-Website des Unternehmens zugänglich sein und für ein Jahr zur Verfügung stehen.
- None.
- None.
United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 23, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023629102/en/
Dewey Steadman at (202) 919-4097 (media/investors)
Harry Silvers at (301) 578-1401 (investors)
https://ir.unither.com/contact-ir
Source: United Therapeutics Corporation
FAQ
When will United Therapeutics (UTHR) report Q3 2024 earnings?
How can I access United Therapeutics (UTHR) Q3 2024 earnings webcast?
How long will United Therapeutics (UTHR) Q3 2024 earnings webcast be available for replay?
